Latest Safety News

The week was split between big earnings reactions and small-cap rocks-and-rigs rallies. Pro Medicus sank despite record numbers, while a handful of explorers jumped on fresh discoveries and policy wins.

Explorers led the Materials tape as fresh drill stories and new ground deals pulled buyers into small caps. Big miners still delivered, but the loudest moves came from companies offering investors a near-term catalyst.

Takeover chatter lit up Pepper Money, while Identitii ran hard after a regulator stepped in. At the other end, AMP slid despite higher profit, as investors weighed leadership change and legal costs.

Big moves came from disclosure drama, CEO change news, and one standout software upgrade. While several stocks jumped on results, a few gaps couldn’t hold as traders sold into early strength.

Paladin Energy reported a 16% increase in uranium production and a significant rise in sales volumes for the December 2025 quarter, alongside a successful equity raise and debt restructuring that enhance its financial flexibility.

Gorilla Gold has secured critical drilling permits for its Comet Vale Gold Project, enabling exploration on high-priority, previously untested targets and expanding its resource potential. New tenure acquisition further broadens the project’s footprint in Western Australia.

Paladin Energy reported a strong half-year performance with uranium sales revenue climbing to US$138.3 million, driven by ramp-up at its Namibian mine and significant progress on Canadian development projects.

Entropy Neurodynamics has been granted an Australian patent for its novel two-phase IV infusion method administering psilocybin and psilocin, securing exclusive rights through 2042 and strengthening its lead asset TRP-8803’s competitive position.

South32 Limited reported a 29% rise in profit for the half year ended December 2025, driven by higher base and precious metals prices and solid operational performance. The company declared a fully-franked interim dividend and maintained its FY26 production guidance, while advancing key projects and managing portfolio transitions.

Orora Limited reported a robust 32.2% rise in underlying net profit after tax for the half-year ended December 2025, underpinned by strong volume growth in its Cans segment and operational efficiencies across its glass businesses. The company also completed a $227.4 million share buyback in 2025 and announced a fresh $270 million on-market buyback program.

IAG’s 1H26 results reveal a 35% drop in net profit after tax due to severe weather costs from its RACQI acquisition, yet underlying insurance profit rose 7.6%, supported by solid premium growth and a $200 million share buyback.

Paradigm Biopharmaceuticals has published a pivotal study in PLOS ONE showing sustained pain relief and joint repair in dogs treated with pentosan polysulfate sodium, reinforcing its potential for human osteoarthritis therapy.